News
10-04-2010, 01:47 AM
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) will be presented at the Ninth International Kidney Cancer Symposium (IKCS) in Chicago, Illinois, October 1-2, 2010.
More... (http://www.news-medical.net/news/20101004/AVEO-Pharmaceuticals-to-present-tivozanib-Phase-2-study-results-at-IKCS-Symposium.aspx)
More... (http://www.news-medical.net/news/20101004/AVEO-Pharmaceuticals-to-present-tivozanib-Phase-2-study-results-at-IKCS-Symposium.aspx)